Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Operational Other
confidence 75%
filed 2026-06-30
EX-99.1
Silicom announced receipt of its first production order for an AI inference solution, marking a transition from development to commercial production and bringing 2026 AI inference revenues into the multi-million-dollar range. This is a material operational and strategic milestone—a significant new customer engagement and product commercialization—but does not fit the discrete event categories (not an earnings release, M&A activity, or workforce action). The disclosure emphasizes this as a "landmark milestone" validating technology and opening a major growth opportunity, making it material to investor assessment of the company's strategic positioning and revenue trajectory.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-06-30
Item 7.01
Blockfusion announced material business developments in connection with its pending SPAC merger: a non-binding anchor lease LOI with a leading AI customer for up to 300 MW (85 MW guaranteed take-or-pay over 15 years, estimated at ~$2.8 billion revenue), a $175 million convertible note financing, and expansion of the Niagara Falls campus.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-30
SK Telecom discloses a mid- to long-term strategic plan to build AI data centers with a total capacity of 15 GW in phases, beginning with 5 GW opening in 2029 and an additional 10 GW from 2035. This is a material operational and strategic initiative responding to AI infrastructure demand, involving significant capital investment and potential partnerships with global technology and overseas investors. While specific investment amounts and timing remain under review, the board resolution of June 29, 2026 and public announcement constitute a material disclosure of a major business expansion plan that would affect a reasonable investor's assessment of the company's strategic direction and capital allocation.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-30
Item 8.01
Stoke Therapeutics announced completion of enrollment of 162 patients in the Phase 3 EMPEROR study of zorevunersen for Dravet syndrome, with anticipated Phase 3 data readout in Q3 2027 and planned rolling NDA submission to the FDA beginning Q1 2027. This represents a material clinical development milestone for the company's lead investigational medicine.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-30
Item 1.01
Aptevo entered into a Grant Award Agreement with the Andy Hill Cancer Research Endowment (CARE) Fund for $1.5 million in non-dilutive research funding to support IND-enabling studies for APVO451, a trispecific antibody candidate. This material research partnership provides external validation and advances a strategic pipeline priority toward clinical development.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-30
The 6-K discloses new radiographic data from Week 104 of the completed ApproaCH pivotal trial of TransCon CNP in children with achondroplasia, presented at an international conference. This represents a material clinical milestone—positive efficacy and safety data from a Phase 3 trial supporting a lead product candidate—but does not fit the discrete event categories (not an earnings release, M&A activity, executive change, or restatement). The disclosure is clearly operational/strategic (clinical trial results) rather than financial, governance, or legal, making operational_other the most appropriate classification.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-30
Item 7.01
Mercer International announced an extension of a maintenance shutdown at its German pulp mill (Mercer Rosenthal) from two weeks to the entire month of September 2026. This is an operational/strategic business event involving a material production facility (360,000 tonnes annual kraft pulp capacity) that would affect investor assessment of near-term production and cash flow. While not fitting a specific named operational category, it is clearly operational in nature and material to a forest products company's performance.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-30
Item 1.01
The filing discloses entry into two material definitive agreements: a Supply Agreement with Orion for manufacture and supply of the Oral Product (with a five-year initial term and automatic renewals), and a Sixth Amendment to the License Agreement extending the regulatory approval milestone to December 31, 2035. While these are contractual arrangements material to the Company's development and commercialization of its levosimendan product, they do not constitute a merger, acquisition, disposition, or change of control (ma_activity), nor do they fit other specific event categories. This is a material operational/strategic agreement that affects the Company's ability to develop and commercialize its product candidate.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-30
Item 8.01
The disclosure announces topline results from a Phase 1 clinical study of vamorolone (AGAMREE), demonstrating on-target glucocorticoid activity without significant immunosuppression at clinical doses. This is a material clinical milestone for a drug candidate that could support expansion into additional chronic inflammatory rare disease indications. While not a traditional earnings release (which reports financial results), this represents a significant operational/clinical development event that would affect investor assessment of the company's pipeline and commercial prospects.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-30
Item 7.01
LQR House announced a two-year agreement with BytePlus (a ByteDance group company) to purchase AI computing power for its subsidiary Fusion Five Continents Securities. This is a material strategic partnership involving a significant technology infrastructure investment to enhance the company's AI-driven research and quantitative modeling capabilities. While the agreement is operational and strategic in nature rather than a specific M&A transaction, debt issuance, or other defined event type, it represents a material business development that would affect a reasonable investor's assessment of the company's strategic direction and competitive positioning in digital finance.
View raw filing on EDGAR →
8-K
Operational Other
confidence 45%
filed 2026-06-30
Item 1.01
Cuentas Inc. entered into a material definitive agreement. The specific nature of the agreement cannot be determined from the Item classification alone, but the disclosure indicates a material operational or strategic arrangement.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-30
EX-99.1
This is an investor presentation disclosing multiple operational and strategic developments in H1 2026, including the sale of a 16.9% stake in Dorad Holdings (NIS 4.4 billion valuation, NIS 254M net proceeds), acceleration of BESS/energy storage projects (3.6 GWh under development), Italy FER X tender awards (2 projects, 67.7 €/MWh tariff), and U.S. solar construction commencement. While the Dorad sale is a significant financial event, the exhibit is primarily a forward-looking operational and strategic presentation covering portfolio progress, geographic expansion, and growth drivers rather than a discrete event announcement. The materiality of the Dorad transaction and strategic repositioning toward energy storage warrants material classification, though the presentation format and mixed operational/financial content make operational_other the most appropriate category.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-30
EX-99.1
This news release discloses a material operational disruption at Silvercorp's China mining operations (Ying and GC mines) triggered by new nationwide safety regulations imposed by Chinese authorities following a coal-mine disaster. The company expects production to be affected by 40–50% in Q3 2026 and 10–15% in the current quarter, with remediation costs of approximately US$11.5 million. While the event is operational in nature (regulatory compliance and production slowdown), it does not fit the specific `workforce_reduction` category (which implies layoffs or restructuring charges) but rather represents a material operational disruption and capital commitment driven by regulatory mandate.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-30
EX-99.1
First Mining announces federal Environmental Assessment approval for the Springpole Gold Project, a major undeveloped gold resource in Ontario. This is a material regulatory milestone enabling project advancement toward construction, representing a significant operational and strategic achievement for the company's development pipeline. The approval removes a key permitting hurdle and validates the project's viability, directly affecting investor assessment of the company's growth prospects and asset value.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-30
EX-99.1
First Mining has entered into a Term Sheet Agreement with Slate Falls Nation establishing key terms for a final Project Agreement governing development of the Springpole Gold Project in northwestern Ontario. This is a material operational and strategic milestone—the agreement details the Indigenous nation's development parameters, environmental protections, regulatory collaboration, and participation in future project design and financial opportunities. While not a completed M&A transaction or binding final agreement, the term sheet represents a significant advancement in permitting and stakeholder engagement for one of the company's two flagship gold projects, directly affecting the project's feasibility and timeline.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-30
EX-99.1
Mesoblast announced receipt of a BLA filing number from the FDA and requested modular review for rexlemestrocel-L in end-stage heart failure patients with LVADs. This represents a material regulatory milestone in the clinical development pathway—the formal submission of a biologics license application to the FDA—which is a significant operational and strategic event for a biopharmaceutical company. While not a discrete event type like M&A or exec change, this regulatory filing milestone materially advances the company's product development program and would affect investor assessment of near-term regulatory prospects.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-30
Item 7.01
Monopar announced that the FDA granted Rare Pediatric Disease (RPD) designation to ALXN1840 for Wilson disease treatment. This is a regulatory milestone that provides potential access to a pediatric Priority Review Voucher (PRV) upon NDA approval, which could accelerate future regulatory reviews. While this is a positive development for a clinical-stage biopharmaceutical company's lead candidate, it is a regulatory/operational milestone rather than a specific named event type (not earnings, M&A, impairment, litigation, etc.). The designation is material to investors as it enhances the value proposition of the company's pipeline and provides a tangible regulatory pathway advantage.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-06-30
Item 7.01
This disclosure announces positive preliminary interim efficacy results from the Phase 2/3 MIRACLE trial of Annamycin for relapsed/refractory AML, showing both treatment arms outperforming control on the primary endpoint of complete remission (43% and 36% vs. 12%). While the results are clinical/operational in nature rather than financial, they represent a material milestone in the company's lead drug development program that would affect a reasonable investor's assessment of the registrant's prospects. This is not an earnings release (no financial results), but rather a material clinical trial milestone disclosure that fits best under operational_other as a significant product/regulatory development.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-30
Item 7.01
Rush Enterprises announced approval for dual listing of its Class A and Class B common stock on Nasdaq Texas, LLC effective July 1, 2026, while maintaining its primary listing on Nasdaq Global Select Market, representing a strategic expansion of capital access.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-30
Item 8.01
Upexi announced a strategic partnership with Blueprint to stake a portion of its Solana holdings. This is a material operational and strategic business event involving the company's core treasury strategy and digital asset management operations. The partnership directly supports the company's stated objective to "maximize yield, enhance operational rigor, and participate responsibly in Solana's long-term growth" and involves staking a significant portion of its over two million SOL holdings. While not fitting a specific named event type, this clearly represents a material operational/strategic milestone that would affect a reasonable investor's assessment of the company's treasury management strategy and capital deployment.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-30
EX-99.1
This news release discloses a fatal workplace incident at Santacruz's Reserva mine in Bolivia on June 24, 2026. While the incident is tragic and the company has suspended operations in the affected area pending investigation, it does not fit the specific taxonomy categories (workforce_reduction applies to planned layoffs/restructuring with exit costs, not fatal accidents). The disclosure is material because it affects investor assessment of operational risk, safety culture, and potential regulatory/legal consequences, but the event itself is an operational safety matter rather than a discrete financial, governance, or legal action. The company's commitment to investigation and operational suspension demonstrates the materiality of the incident to stakeholders.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-30
EX-99.1
PowerBank announces execution of a 21-megawatt Operations and Maintenance Services Agreement with Honeywell for three community solar projects in New York State. This is a material operational and strategic milestone demonstrating the company's vertically integrated business model (development, EPC, and O&M services) and represents a long-term revenue-generating contract following successful project commissioning. The agreement reflects the company's competitive positioning and customer trust, making it material to investors assessing the company's operational capabilities and growth trajectory.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-06-30
The filing discloses two operational/capital allocation events: (1) acquisition of 10,000 ETH for ~$16.1 million, bringing total ETH holdings to 886,725, and (2) repurchase of 2,132,773 shares at $4.69/share under the 2025 Repurchase Program. These represent material treasury management and capital allocation decisions for a company whose stated strategy centers on growing ETH per share, but neither fits the specific taxonomy categories (not a debt issuance, dividend, M&A, or workforce action). The ETH acquisition and share buyback are operational/strategic capital deployment decisions material to investors assessing the company's resource allocation.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-06-30
Item 8.01
Microbot Medical entered into a strategic manufacturing agreement with Sanmina Corporation to expand production capacity for its LIBERTY System. The press release emphasizes this as part of the company's cost reduction strategy and operational scaling to meet rising demand across U.S. and international markets. While this is a material operational and strategic business event—involving a significant partnership with a global contract manufacturer to support commercialization and margin improvement—it does not fit the specific categories of M&A activity, debt issuance, or other named financial/legal events. This is best classified as an operational partnership/contract milestone.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-30
Item 8.01
Akebia announced positive interim analysis results from the VOICE trial demonstrating that Vafseo (vadadustat) met predefined stopping criteria by establishing non-inferiority and superiority on the primary composite endpoint of mortality and hospitalization, with a statistically significant reduction in hospitalizations versus standard-of-care ESA. This represents a material clinical milestone for the company's marketed product, providing significant positive clinical evidence supporting the commercial viability and differentiation of Vafseo in the dialysis anemia market.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-30
EX-99.1
Trinity Biotech announced that its Trinovium subsidiary has secured Silver Membership in the Open Compute Project (OCP), a major industry consortium shaping data center infrastructure standards. This is a strategic operational milestone enabling Trinovium to engage with hyperscale customers and participate in standards development for AI data center liquid cooling—a market projected to grow from $4 billion to $27 billion by 2033. While not a discrete M&A transaction, debt issuance, or earnings event, this represents a material strategic partnership and market-access achievement that would affect a reasonable investor's assessment of Trinity Biotech's ability to commercialize its Trinovium subsidiary and compete in the high-growth liquid cooling sector.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-30
Item 8.01
Vistagen announced topline results from the PALISADE-4 Phase 3 trial of fasedienol for social anxiety disorder, which failed to achieve its primary endpoint (p=0.427) in the overall population, though post-hoc analysis showed nominal statistical significance in a severe subpopulation. This material clinical development setback for the company's most advanced product candidate was disclosed via press release and conference call.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-30
Item 7.01
TRSO's controlled subsidiary Goldfinch-Chong has entered into a strategic cooperation agreement with Sichuan Wochuang involving an initial RMB 200 million ($30 million USD) capital investment to expand AI-enabled electric two-wheeler charging infrastructure in China. This is a material operational and strategic business event—a significant partnership with substantial capital commitment that advances the company's new-energy infrastructure strategy and market expansion goals. While not a traditional M&A transaction, the scale and strategic importance to TRSO's business transformation warrant materiality classification.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-06-30
Item 7.01
NovoCure announced that Optune Pax® received CE Mark approval for treating locally advanced pancreatic cancer, supported by Phase 3 PANOVA-3 trial data showing statistically significant improvement in overall survival and pain progression delay. This is a material regulatory milestone and product approval event that is operational/commercial in nature—the company is expanding market access for a key product—but does not fit the specific categories of earnings release, M&A, impairment, or other defined event types. The disclosure is material because regulatory approvals and product launches directly affect revenue prospects and competitive positioning.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-30
Guardian Metal Resources announced completion of a Pre-Feasibility Study (PFS) for its Pilot Mountain tungsten project, showing positive economics (NPV8 of US$660.3M, IRR of 59.6% at base case pricing). This is a material operational and strategic milestone—the PFS completion marks a critical step toward potential mine development and production targeted for Q4 2028. While not a discrete M&A transaction, earnings release, or governance event, the PFS represents a significant advancement in the company's development pathway and would materially affect investor assessment of the project's viability and the company's strategic position in the critical minerals sector.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-30
Item 7.01
WidePoint discloses notification of a post-award protest filed against its $3.1 billion DHS CWMS 3.0 contract award. While the company believes the protest is without merit and expects to retain the contract, the filing of a protest against a material government contract represents a material operational and legal risk event that could affect the registrant's ability to realize the benefits of this significant award. This is a legal/regulatory challenge to a major contract rather than a routine administrative matter.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-06-30
Item 8.01
Vivani announced receipt of regulatory approval from Bellberry (an Australian human research ethics committee) to initiate SLIM-1, a Phase 1 clinical trial of NPM-139, a semaglutide implant, representing a material clinical development milestone for the company's drug pipeline.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-06-30
Item 7.01
Vivakor entered into a new recurring crude oil transaction through Enterprise Products Cushing Terminal generating approximately $90 million in annualized gross revenue, expanding the company's contracted revenue to approximately $420 million and progressing toward a $1 billion objective.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-30
Item 7.01
D-Wave announced receipt of a $1.566 million NSF grant through the National Quantum Virtual Laboratory program to support its role as a key industry partner in the ERASE project focused on fault-tolerant quantum computing. This is a material operational and strategic event—a significant government funding award and research partnership that validates D-Wave's technology and strengthens its competitive position in quantum computing. While not fitting a specific named category, this is clearly an operational/strategic milestone rather than a financial obligation, M&A activity, or governance matter.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-29
EX-99.1
DHT announces proactive design upgrades to two newbuilding crude oil tankers (DHT Impala and DHT Gazelle) to enhance trading eligibility and commercial flexibility. This is an operational and strategic business decision affecting fleet deployment and vessel specifications. While not a discrete M&A event, covenant breach, or financial obligation, the upgrade schedule and charter continuity measures (substituting DHT Gazelle with DHT Addax) represent material operational changes that would affect investor assessment of fleet readiness and revenue continuity.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-29
EX-99.1
Zentek announced entry into an exclusive licensing agreement with Applied Silver Inc. dated June 26, 2026, granting rights to incorporate silver technology into ZenGUARD™ Enhanced Air Filtration Media for U.S. market commercialization across HVAC, healthcare, residential, and other applications. This is a material strategic partnership and commercialization milestone that advances the company's business strategy and market access, but does not constitute a discrete M&A transaction, debt issuance, or other specifically-named event type—it is a material operational/commercial agreement that would affect investor assessment of the company's growth prospects.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-29
EX-99.1
This press release announces a long-term supplier agreement between Vertical Aerospace and Astronics Corporation for the low-voltage power distribution system on Vertical's Valo eVTOL aircraft. The disclosure is a material operational/strategic event—it represents a significant supply-chain commitment for a critical aircraft system as Vertical advances toward certification and commercial production. While not a discrete M&A transaction, it is a material commercial arrangement that would affect a reasonable investor's assessment of Vertical's progress toward certification and production readiness.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-29
EX-99.1
This is a comprehensive technical report on the Curipamba-El Domo polymetallic project in Ecuador, prepared by SRK Consulting for Silvercorp Metals Inc. The report contains mineral resource and reserve estimates, mining and processing plans, environmental assessments, and economic analysis. While technical reports are standard industry practice for mining projects, this document discloses material operational and strategic information about the project's development status, resource base, and economic viability that would be relevant to investors assessing the company's asset base and future production potential.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-06-29
Item 8.01
The disclosure announces FDA authorization of an Investigational New Drug (IND) application for GT-02287, enabling the company to initiate Phase 2 clinical development in Parkinson's disease. This is a material regulatory milestone in the drug development pipeline that would affect a reasonable investor's assessment of the company's progress and prospects, but does not fit the specific categories of earnings, M&A, impairment, litigation, or other named event types. It is clearly an operational/strategic business milestone.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-29
EX-99.1
This press release announces FDA Fast Track designation for SAT-3247 in Duchenne muscular dystrophy, a regulatory milestone that accelerates development and review timelines. While not a discrete M&A, financing, or personnel event, the Fast Track designation—combined with existing Orphan Drug and Rare Pediatric Disease designations—materially advances the clinical program's regulatory pathway and represents a significant operational/strategic achievement for a clinical-stage biotech company. The designation is material to investors assessing the company's progress toward commercialization.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-29
EX-99.1
This press release announces positive real-world clinical data from a 462-patient study showing 83.5% response rate in comorbid PTSD and MDD patients treated with Deep TMS. While the data is preliminary and not yet FDA-cleared for these indications, the announcement of significant clinical evidence supporting the company's core product platform in a large patient population represents a material operational/clinical milestone that would affect investor assessment of the company's pipeline and commercial prospects. The study is the "largest real-world analysis" to date in this patient population, strengthening the clinical evidence base for the company's technology.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-29
The filing announces receipt of $43 million in additional orders for Sidewinder ESA terminals from a major in-flight connectivity service provider, with deliveries planned over 18 months. This represents a material operational and commercial milestone—a significant customer order that validates product demand and supports business growth—but does not fit the discrete event categories (not an earnings release, M&A activity, executive change, or financial obligation). The order is material to a reasonable investor assessing the registrant's revenue trajectory and market position.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-29
EX-99.1
This is an investor presentation disclosing Perion's strategic positioning, product roadmap (Perion One platform and Outmax AI agent), financial guidance for 2026 (Contribution ex-TAC $215M–$235M, Adjusted EBITDA $50M–$54M), and multiple new partnership announcements (Amazon DSP, Walmart Connect, Mastercard, Best Buy Canada, Albertsons, McSorely/Mediamark). While it contains forward-looking statements and operational metrics, it is fundamentally a strategic and business development disclosure rather than a discrete event (M&A, executive change, earnings release, or financial restatement). The partnerships and platform developments are material to investor assessment of the company's growth trajectory and competitive positioning, but the exhibit is primarily a presentation of ongoing business strategy and operational progress rather than a single material event.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-29
Item 8.01
Larimar announced submission of the first module of a rolling Biologics License Application (BLA) to the FDA for accelerated approval of nomlabofusp for Friedreich's ataxia, along with positive long-term open-label study data showing sustained skin frataxin (FXN) levels and directional clinical improvements. This is a material regulatory and clinical milestone for a clinical-stage biotech company, but does not fit neatly into the specific event categories (not an earnings release, M&A activity, impairment, or other defined types). The disclosure centers on a significant product development and regulatory advancement that would affect a reasonable investor's assessment of the company's progress toward commercialization.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-06-29
EX-99.1
This press release announces the integration of Saber Money into OwlPay Harbor, expanding OwlTing's cross-border payment infrastructure into India's US$860 billion export economy with direct rupee settlement and Eurozone/UK payment access. The disclosure describes a material operational and strategic milestone—opening a major new payment corridor and revenue opportunity—that aligns with management's stated 2026 objective of converting infrastructure into production client relationships and revenue. While not a discrete M&A transaction, the integration represents a significant expansion of the Company's addressable market and operational capabilities.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-06-29
Item 8.01
Evommune announced that its Phase 2b clinical trial of EVO756 failed to meet its primary endpoint in chronic spontaneous urticaria, leading the company to cease development in this indication while continuing evaluation in atopic dermatitis and migraine. This material clinical development setback represents a significant strategic pivot affecting the company's pipeline and investor assessment of its progress.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-06-29
EX-99.1
This press release announces the completion of Optimi's third commercial psilocybin export shipment to Australia (1,000 capsules of 5mg psilocybin for treatment-resistant depression), marking ongoing commercial revenue generation from a regulated market. The disclosure emphasizes the company's commercial-stage operations, expanding reimbursement coverage from public and private insurers, and the absence of serious adverse events. While this is an operational milestone reflecting the company's ability to execute its business model in a regulated psychedelic medicine market, it does not fit the discrete event categories (M&A, earnings release, executive changes, debt issuance, etc.) and is best classified as an operational business development event.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-06-29
Item 7.01
The fund disclosed new investment commitments of approximately $102.5 million in debt instruments (Invited, Inc. and AWP Group Holdings, Inc.) made subsequent to March 31, 2026, along with portfolio characteristics as of June 23, 2026. This represents material capital deployment and portfolio composition changes for the investment fund.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-29
Item 8.01
DBV Technologies disclosed a regulatory milestone update regarding its BLA (Biologics License Application) submission for VIASKIN® Peanut Patch in children aged 4-7 years. The company reported productive FDA engagement, confirmation that no additional data was requested, and a revised timeline for BLA submission to Q3 2026. This is a material operational/regulatory event affecting the company's product development trajectory and investor expectations, but does not fit the specific categories of earnings release, M&A activity, impairment, or other defined event types. The disclosure centers on a strategic regulatory milestone rather than a discrete operational restructuring or contract.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-06-29
Item 8.01
Star Equity Holdings announced its inclusion in the Russell Microcap Index following the 2026 reconstitution, effective June 26, 2026. While this is a positive operational/strategic milestone that increases institutional visibility and investor awareness, it does not fit neatly into any specific event category. The company characterizes it as "a meaningful milestone" that "expands our visibility within the institutional investment community." This is a material operational event reflecting market recognition and improved access to capital markets, but it is not a governance matter, financial obligation, M&A activity, or other named event type.
View raw filing on EDGAR →